Differentiated Thyroid Carcinoma: A Polygenic Disease

Links, Thera P.; Tol, Karin M. van; Meerman, Gerard J. te; Vries, Elisabeth G.E. de

doi:10.1089/10507250152740975

Cited by 19 publications

(8 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depending on type and size of the tumor, hemithyroidectomy can suffice. The removal of the thyroid gland is accompanied by a lifelong dependence on substitution therapy with levothyroxine and in the first two years with dosing regimens suppressing thyrotropin (TSH) production (4,5), causing subclinical hyperthyroidism. Despite the efficacy of these primary treatments and the high long-term survival rates, the disease can recur even decades later.…”

Section: Introductionmentioning

confidence: 99%

Fatigue Among Short- and Long-Term Thyroid Cancer Survivors: Results from the Population-Based PROFILES Registry

Husson

Nieuwlaat

Oranje

et al. 2013

Thyroid

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Fatigue Among Short- and Long-Term Thyroid Cancer Survivors: Results from the Population-Based PROFILES Registry

Husson

Nieuwlaat

Oranje

et al. 2013

Thyroid

View full text Add to dashboard Cite

show abstract

“…The follicular-derived neoplasms (adenoma, carcinoma, and the follicular variant of papillary carcinoma) manifest overlapping cytomorphologic features and not infrequently pose diagnostic and treatment difficulties (1)(2)(3)(4). Previous molecular studies of thyroid tumors have been limited to individual or multiple targeted markers and have failed to define any diagnostic or prognostic markers (5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Gene Expression Profiling of Differentiated Thyroid Neoplasms

Chevillard¹,

Ugolin²,

Vielh

et al. 2004

Clinical Cancer Research

120

View full text Add to dashboard Cite

Purpose: The purpose of this research was to identify novel genes that can be targeted as diagnostic and clinical markers of differentiated thyroid tumors.Experimental Design: Gene expression analysis using microarray platform was performed on 6 pathologically normal thyroid samples and 12 primary follicular and papillary thyroid neoplasms. Microarrays containing probes for 5,760 human full-length cDNAs were used for hybridization with total RNA from normal and tumor thyroid samples labeled with Cy3-dUTP and Cy5-dUTP, respectively. Scanned array images were recorded, and data analysis was performed. Selected sets of differentially expressed genes were analyzed using quantitative real-time reverse transcription-PCR for verification.Results: We identified 155 genes that differentiate histologically normal thyroid tissues from benign and malignant thyroid neoplasms. Of these 75 genes were differentiated between follicular neoplasms (adenoma and carcinoma) and the follicular variant of papillary carcinoma. Purely follicular neoplasms (adenomas and carcinomas) shared many genetic profiles, and only 43 genes were distinctly different between these tumors. Hierarchical cluster analysis also differentiated conventional papillary carcinoma from its follicular variant and follicular tumors. The differentially expressed genes were composed of members of cell differentiation, adhesion, immune response, and proliferation associated pathways. Quantitative real-time reverse transcription-PCR analysis of selected genes corroborated the microarray expression results.Conclusions: Our study show the following: (1) differences in gene expression between tumor and nontumor bearing normal thyroid tissue can be identified, (2) a set of genes differentiate follicular neoplasm from follicular variant of papillary carcinoma, (3) follicular adenoma and carcinoma share many of the differentiated genes, and (4) gene expression differences identify conventional papillary carcinoma from the follicular variant.

show abstract

“…Se calcula que entre el 7-10 % de los carcinomas diferenciados (no medulares) hay agrupación familiar 30 . Estos presentan como rasgos característicos un inicio temprano y un comportamiento agresivo.…”

Section: Síndromes Familiaresunclassified

Biología molecular del carcinoma de tiroides de estirpe folicular (II). Aplicaciones clínicas

Galofré

Calleja

Panizo

et al. 2018

revista-de-medicina

View full text Add to dashboard Cite

El notable avance que ha experimentado la medicina molecular en los últimos años proporciona una visión tremendamente atractiva sobre las nuevas posibilidades de abordaje diagnóstico y terapéutico del carcinoma de tiroides, a la vez que nos ayuda a comprender su comportamiento biológico. La aplicación clínica de dichos hallazgos comienza a ser una realidad. Este conocimiento puede proporcionar información para esclarecer un diagnóstico dudoso, distinguir las células malignas de las benignas, predecir la agresividad de un tumor o indicar su origen. Del mismo modo puede resultar útil para conocer las posibilidades de respuesta al tratamiento convencional más adecuado, o las implicaciones que tendrá el emergente campo de la farmacogenética. Del mismo modo las aplicaciones de la medicina molecular deben ser tenidas en cuenta en los estudios de orientación pronóstica tanto en los tumores espontáneos como en las neoplasias de origen familiar. Dicha información puede mejorar de forma importante las limitaciones actuales de los métodos de pronóstico basados en criterios clinico-patológicos.

show abstract

Differentiated Thyroid Carcinoma: A Polygenic Disease

Cited by 19 publications

References 62 publications

Fatigue Among Short- and Long-Term Thyroid Cancer Survivors: Results from the Population-Based PROFILES Registry

Fatigue Among Short- and Long-Term Thyroid Cancer Survivors: Results from the Population-Based PROFILES Registry

Gene Expression Profiling of Differentiated Thyroid Neoplasms

Biología molecular del carcinoma de tiroides de estirpe folicular (II). Aplicaciones clínicas

Contact Info

Product

Resources

About